All GLG News Analyses Filed Under: Cardiology
Analyses are solely the work of the authors and have not been edited or endorsed by GLG.
-
Abbott to become a comprehensive structural heart disease provider
September 14, 2009
Abbott To Acquire Evalve, Inc., A Leader In Minimally Invasive Cardiac Valve Repair Technology | www.medicalnewstoday.com
With the acquisition of Evalve, Abbott will position itself on the lead for structural heart disease.
-
MADIT CRT Will Increase Use of CRT Defibrillators
September 2, 2009
Cardiac-Resynchronization Therapy for the Prevention of Heart Failure Events | content.nejm.org
MADIT CRT was designed to assess if an ICD with CRT (vs. ICD alone) affected a combined endpoint of death or heart failure events in patients with mild cardiac symptoms. Over a mean of 2.4 years, the endpoint differed between groups due to a 41% reduction in heart failure events. Those who benefitted the most were those with a QRS of at least 150 ms. Mortality was similar with or without CRT; it was low. ICD with CRT decreased risk of heart failure events in this population.
-
Antiplatelet drugs in a horse race
September 1, 2009
Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients | www.pipelinereview.com
Acute coronary patients who undergo angioplasty & stenting are treated with 2 inhibitors of platelet aggregation: aspirin, & clopidogrel. Recently we've seen a new entry to the market that has been nearly monopolized by clopidogrel, in Lilly's drug prasugrel. And now a 3rd drug, ticagrelor, looks likely to follow. There are significant but subtle differences among the 3, and clopidogrel will have a generic version soon, presumably further increasing the cost advantage for the older drug.
-
MADIT-CRT trial - How will it impact the ICD/CRT market
September 1, 2009
Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events (MADIT-CRT trial) | content.nejm.org
The MADIT CRT trial evaluated the benefit of cardiac resynchronization therapy for patients with reduced ejection fraction and mild cardiac symptoms. Previous studies have shown a benefit of CRT for patients with more severe cardiac symptoms. The trial demonstrated a significant reduction in the composite endpoint of heart failure events and death from CRT therapy. The of benefit was in the heart failure events component of the combined endpoint (as opposed to the mortality component).
-
Dibigatran will change how we manage atrial fibrillation
August 31, 2009
Dabigatran versus Warfarin in Patients with Atrial Fibrillation | www.theheart.org
In patients with atrial fibrillation, rates of stroke and embolism are similar comparing dabigatran, 110 mg, to adjusted dose warfarin. Rates of major hemorrhage were lower with dibigatran. Dibigatran at a 150 mg fixed dose is associated with lower rates of stroke and systemic embolism but similar rates of major hemorrhage compared to warfarin. Reference: Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361.
-
Finally an alternative to Warfarin for patients with Atrial Fibrillation
August 31, 2009
New Blood Thinner Matches Warfarin | online.wsj.com
1) Dabigatran, a new drug from Boehringer Ingleheim GmbH, is found to be as effective as warfarin in preventing stoke.2) This will likely change the way medicine is practiced once the drug is approved by the FDA
-
July 20, 2009
FDA: Ongoing Omalizumab Study Shows Increased Number of Cardiovascular Events | www.docguide.com
Increased events likely from increased leukotrienes would be very hazardous as many smokers have lung and hear disease limiting its use in these situations.
-
July 19, 2009
FDA: Ongoing Omalizumab Study Shows Increased Number of Cardiovascular Events | www.docguide.com
"The interim data, submitted by the manufacturer of Xolair , suggest a disproportionate increase in ischemic heart disease, arrhythmias, cardiomyopathy and cardiac failure, pulmonary hypertension, cerebrovascular disorders, and embolic, thrombotic and thrombophlebitic events in patients treated with Xolair compared to the control group of patients not given the drug," according to the FDA's announcement.
-
Novartis Targets Global Renin Angiotensin System Inhibition
July 12, 2009
High blood pressure medicine Rasilez gets approval in Japan | www.pharmabiz.com
It has taken a long, long time form oral renin inhibition to come along, and Novartis is seeking to target glomeruli on 5 continents. The South East Asian market is potentially huge for the treatment of hypertension and Japan has a long tradition of willingness to participate in the battle to lower blood pressure by all means pharmacological. Whilst there are still few data to demonstrate superiority of Direct Renin inhibition over ACE inhibition in long term outcomes, the field of hypertension treatment is still expanding, no doubt in part, driven by consumer demand for the newest agent, and the side-effects, real, important or otherwise of current agents often reported more in anecdote than evidence based format. Novartis has an important role in the area of Renin-Angiotensin System inhibition, and this new approval will do no harm to that reputation and market share.
-
May 5, 2009
The effect on reduces LDL cholesterol is more important so that reduce the risk of atherosclerosis. The effect on C-reactive protein is maybe one of the explication. Maybe other effect unknown. The adverse effect are not important. The impact must be important. We must prescribe more atorvastatine and less simvastatine.
- Subscribe to Updates
-
Leading institutions connect with members of the Healthcare councils through GLG
Get Intelligently Connected
with the world's leading experts
GLG's 850+ Clients Include:
- More than 70% of the world's leading
- mutual funds
- 15 of the leading 20
- global banks
- 7 of the leading 10
- global private equity firms
- 5 of the leading 10
- AmLaw firms
- Fortune 500® Companies
- in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software
Most Popular Cardiology News
-
Zetia Now Off Best Practices List for MI Prevention, But is Niaspan > Diet?
November 15, 2009
-
Percutaneous valve repair – next battle among cardiovascular device companies?
October 4, 2009
-
MADIT CRT Will Increase Use of CRT Defibrillators
September 2, 2009
-
Dibigatran will change how we manage atrial fibrillation
August 31, 2009
-
Finally an alternative to Warfarin for patients with Atrial Fibrillation
August 31, 2009